These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
367 related articles for article (PubMed ID: 9543145)
1. Soluble intercellular adhesion molecule-1 (sICAM-1) concentrations in Graves' disease patients followed up for development of ophthalmopathy. De Bellis A; Di Martino S; Fiordelisi F; Muccitelli VI; Sinisi AA; Abbate GF; Gargano D; Bellastella A; Bizzarro A J Clin Endocrinol Metab; 1998 Apr; 83(4):1222-5. PubMed ID: 9543145 [TBL] [Abstract][Full Text] [Related]
2. Behavior of soluble intercellular adhesion molecule-1 and endothelial-leukocyte adhesion molecule-1 concentrations in patients with Graves' disease with or without ophthalmopathy and in patients with toxic adenoma. De Bellis A; Bizzarro A; Gattoni A; Romano C; Di Martino S; Sinisi AA; Abbadessa S; Bellastella A J Clin Endocrinol Metab; 1995 Jul; 80(7):2118-21. PubMed ID: 7541801 [TBL] [Abstract][Full Text] [Related]
3. Serum antibodies to collagen XIII: a further good marker of active Graves' ophthalmopathy. De Bellis A; Sansone D; Coronella C; Conte M; Iorio S; Perrino S; Battaglia M; Bellastella G; Wall JR; Bellastella A; Bizzarro A Clin Endocrinol (Oxf); 2005 Jan; 62(1):24-9. PubMed ID: 15638866 [TBL] [Abstract][Full Text] [Related]
4. Soluble intercellular adhesion molecule-1 (sICAM-1) in sera of patients with Graves' ophthalmopathy and thyroid diseases. Heufelder AE; Bahn RS Clin Exp Immunol; 1993 May; 92(2):296-302. PubMed ID: 8097976 [TBL] [Abstract][Full Text] [Related]
5. [Soluble forms of adhesion molecules sELAM-1 and sICAM-1 in Graves disease and toxic nodular goiter]. Modelska-Ziółkiewicz A; Gembicki M; Sowiński J Pol Arch Med Wewn; 2003 May; 109(5):463-8. PubMed ID: 14768174 [TBL] [Abstract][Full Text] [Related]
6. Soluble intercellular adhesion molecule-1 concentrations in patients with subacute thyroiditis and in patients with Graves' disease with or without ophthalmopathy. Ozata M; Bolu E; Sengül A; Altinsoy HI; Turan M; Corakci A; Hacibektasoglu A; Gundogan MA Endocr J; 1996 Oct; 43(5):517-25. PubMed ID: 8980891 [TBL] [Abstract][Full Text] [Related]
7. Soluble intercellular adhesion molecule-1 (sICAM-1) in Graves' disease. Balázs C; Kiss E Acta Microbiol Immunol Hung; 1994; 41(4):451-6. PubMed ID: 7866729 [TBL] [Abstract][Full Text] [Related]
8. [Usefulness of soluble ICAM-1 measurements for the evaluation of the disease activity and efficiency of therapy in patients with infiltrative Graves' ophthalmopathy]. Kulig G; Pilarska K; Kulig J; Krzyzanowska-Swiniarska B; Robaczyk M; Baraniak A Pol Arch Med Wewn; 2002 Dec; 108(6):1161-9. PubMed ID: 12687928 [TBL] [Abstract][Full Text] [Related]
9. Smoking and disease severity are independent determinants of serum adhesion molecule levels in Graves' ophthalmopathy. Wakelkamp IM; Gerding MN; van der Meer JW; Prummel MF; Wiersinga WM Clin Exp Immunol; 2002 Feb; 127(2):316-20. PubMed ID: 11876756 [TBL] [Abstract][Full Text] [Related]
10. Intercellular adhesion molecule-1 (ICAM-1) in the sera of patients with Graves' disease: correlation with disease activity and treatment status. Fukazawa H; Yoshida K; Kaise N; Kiso Y; Sayama N; Mori K; Kikuchi K; Aizawa Y; Rikimaru A; Abe K Thyroid; 1995 Oct; 5(5):373-7. PubMed ID: 8563475 [TBL] [Abstract][Full Text] [Related]
11. [Prognostic role of adhesion molecules sELAM-1 and sICAM-1 in glucocorticoid therapy of active ophthalmopathy]. Modelska-Ziółkiewicz A; Gembicki M; Bednarek J; Sowiński J Pol Arch Med Wewn; 2003 May; 109(5):469-75. PubMed ID: 14768175 [TBL] [Abstract][Full Text] [Related]
12. Extraocular muscle antibodies and the occurrence of ophthalmopathy in Graves' disease. de Bellis A; Perrino S; Coronella C; Sansone D; Ruocco G; Tirelli G; Di Martino S; Conte M; Bellastella G; Wall JR; Bellastella A; Bizzarro A Clin Endocrinol (Oxf); 2004 Jun; 60(6):694-8. PubMed ID: 15163332 [TBL] [Abstract][Full Text] [Related]
13. Relationship between longitudinal behaviour of some markers of eye autoimmunity and changes in ocular findings in patients with Graves' ophthalmopathy receiving corticosteroid therapy. De Bellis A; Bizzarro A; Conte M; Coronella C; Solimeno S; Perrino S; Sansone D; Guaglione M; Wall JR; Bellastella A Clin Endocrinol (Oxf); 2003 Sep; 59(3):388-95. PubMed ID: 12919164 [TBL] [Abstract][Full Text] [Related]